Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report)’s stock price traded up 8.7% during trading on Tuesday . The stock traded as high as $0.11 and last traded at $0.10. 32,615,548 shares were traded during trading, an increase of 1,470% from the average session volume of 2,076,846 shares. The stock had previously closed at $0.09.
Petros Pharmaceuticals Stock Performance
The stock’s 50 day moving average is $0.25 and its two-hundred day moving average is $0.30. The firm has a market capitalization of $1.16 million, a P/E ratio of -0.02 and a beta of 2.04. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Recommended Stories
- Five stocks we like better than Petros Pharmaceuticals
- Want to Profit on the Downtrend? Downtrends, Explained.
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Quiet Period Expirations Explained
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Stock Average Calculator
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
